InTrack Investment Management Inc Decreases Stake in Danaher Co. (NYSE:DHR)

InTrack Investment Management Inc lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 8.7% in the 1st quarter, Holdings Channel reports. The fund owned 6,806 shares of the conglomerate’s stock after selling 651 shares during the quarter. Danaher accounts for 1.3% of InTrack Investment Management Inc’s holdings, making the stock its 18th largest holding. InTrack Investment Management Inc’s holdings in Danaher were worth $1,700,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC grew its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock worth $37,536,717 over the last 90 days. 10.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DHR. Evercore ISI reduced their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday. Bank of America lifted their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. TD Cowen raised their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.67.

Danaher Stock Down 1.7 %

Shares of NYSE:DHR traded down $4.10 during trading on Tuesday, hitting $240.41. The company’s stock had a trading volume of 5,062,756 shares, compared to its average volume of 2,876,110. The company has a market capitalization of $178.07 billion, a PE ratio of 40.75, a P/E/G ratio of 3.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The business has a 50 day moving average price of $256.13 and a two-hundred day moving average price of $246.86.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.36 EPS. As a group, research analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.